ERRATUM

Me too-drugs with limited benefits — the tale of regorafenib for HCC

*Bishal Gyawali and Vinay Prasad**Nature Reviews Clinical Oncology* **14**, 653–654 (2017)

In the illustration that accompanies this article, the structures of regorafenib and sorafenib were incorrectly drawn. In both structures, a double bond was omitted from the central phenyl ring so that it appeared as a 1,3-cyclohexadiene. The figure has been corrected in both the HTML and PDF versions of this News & Views.